ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer

Allum, William; Lordick, Florian; Alsina, María; Andritsch, Elisabeth; Ba‐Ssalamah, Ahmed; Beishon, Marc; Braga, Marco; Caballero, Carmela; Carneiro, Fátima; Cassinello, Fernando; Dekker, Jan Willem T.; Delgado-Bolton, Roberto; Haustermans, Karin; Henning, Geoffrey; Hutter, Bettina; Lövey, József; Netikova, Irena Stenglova; Obermannová, Radka; Oberst, Simon; Rostoft, Siri; Saarto, Tiina; Seufferlein, Thomas; Sheth, Sapna; Wynter-Blyth, Venetia; Costa, Alberto; Naredi, Peter

doi:10.1016/j.critrevonc.2017.12.019

Cited by 60 publications

(59 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expert preferences vary considerably depending on the tumour location, extent, histological subtype and comorbidities. There is no simple 'one-size-fits-all' approach [1], and any treatment decision requires an interdisciplinary discussion in a comprehensive multidisciplinary setting.…”

Section: Neoadjuvant Treatment Of Aegmentioning

confidence: 99%

“…The topic of the 4th St. Gallen EORTC Gastrointestinal Cancer Conference 2018 was the primary approach to patients with potentially curable adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus, three anatomically defined tumour locations with distinct, although overlapping, molecular features and treatment strategies [1]. Differences in histopathology can be used to distinguish between intestinal-type gastric cancer and diffuse type according to the Lauren classification.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma

Lutz

Zalcberg

Ducreux

et al. 2019

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Multimodal primary treatment of localised adenocarcinoma of the stomach, the oesophagus and the oesophagogastric junction (AEG) was reviewed by a multidisciplinary expert panel in a moderated consensus session. Here, we report the key points of the discussion and the resulting recommendations. The exact definition of the tumour location and extent by white light endoscopy in conjunction with computed tomography scans is the backbone for any treatment decision. Their value is limited with respect to the infiltration depth, lymph node involvement and peritoneal involvement. Additional endoscopic ultrasound was recommended mainly for tumours of the lower oesophagogastric junction (i.e. AEG type II and III according to Siewert) and in early cancers before endoscopic resection. Laparoscopy to diagnose peritoneal involvement was thought to be necessary before the start of neoadjuvant treatment in all gastric cancers and in AEG type II and III. In general, perioperative multimodal treatment was suggested for all locally advanced oesophageal tumours and for gastric cancers with a clinical stage above T1N0. There was consensus that the combination of fluorouracil, folinic acid, oxaliplatin and docetaxel is now a new standard chemotherapy (CTx) regimen for fit patients. In contrast, the optimal choice of perioperative CTx versus neoadjuvant radiochemotherapy (neoRCTx), especially for AEG, was identified as an open question. Expert treatment recommendations depend on the tumour location, biology, the risk of incomplete (R1) resection, response to treatment, local or systemic recurrence risks, the predicted perioperative morbidity and patients' comorbidities. In summary, any treatment decision requires an interdisciplinary discussion in a comprehensive multidisciplinary setting. ª

show abstract

Section: Neoadjuvant Treatment Of Aegmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma

Lutz

Zalcberg

Ducreux

et al. 2019

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…8 In, Europe the highest rate of oesophageal cancer is in Western European countries, including the UK, Netherlands, Ireland and Belgium. 9 In Sweden, approximately 450-500 new cases of oesophageal cancer were diagnosed in 2016 and it is therefore considered a rare cancer disease, in similarity with the other Nordic countries. 10,11 Oesophageal cancer and adenocarcinoma have been reported with a male to female ratio in incidence of 2.4:1 to 9:1.…”

Section: Epidemiology Of Oesophageal Cancermentioning

confidence: 99%

Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial

Sunde

Johnsen

Jacobsen

et al. 2018

Diseases of the Esophagus

View full text Add to dashboard Cite

Dysphagia is the most significant symptom in patients with esophageal cancer. There are different therapeutic interventions designed to relieve dysphagia, but few studies have addressed the effects of neoadjuvant therapy. The aim of this study is to compare the effects on dysphagia of neoadjuvant chemotherapy (nCT) versus neoadjuvant chemoradiotherapy (nCRT) and further to study the association between dysphagia response and histological response. Patient reported swallowing function was a secondary endpoint in the NeoRes trial, in which patients were randomized between neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy. Patients completed dysphagia questionnaires before the start and after neoadjuvant therapy, using the European Organization for Research and Treatment of Cancer (EORTC) esophageal cancer modules QLQ-OES24/OG25. Chirieac tumor regression grade (TRG) was used to assess the histological response. Out of 181 patients were randomized, of whom 87% completed the dysphagia questionnaires before and 73% after neoadjuvant treatment. Patient characteristics were similar between the treatment arms. Among patients reporting dysphagia at baseline, neoadjuvant therapy improved dysphagia in both arms. The mean dysphagia score after neoadjuvant treatment was significantly lower after nCT compared to after nCRT (P = 0.022). The reported dysphagia did not differ between those with a complete histological response (TRG 1) and those without any response at all (TRG 4) (P = 0. 583).

show abstract

“…[3][4][5][6] Dysphagia, chest pain, gastrointestinal bleeding, asthenia, weight loss, fever, nausea, and vomiting are the most frequent symptoms, which worsen quality of life. 2,[7][8][9] Moreover, dysphagia can also dramatically reduce nutritional support and lead to malnutrition, anorexia, and dehydration. 10 Several effective options, such as intraluminal stents, brachytherapy, and endoscopic treatment of obstruction or stenosis with laser or cryotherapy, are available for symptom palliation.…”

Section: Introductionmentioning

confidence: 99%

Short-Course 2-Dimensional Radiation Therapy in the Palliative Treatment of Esophageal Cancer in a Developing Country: A Phase II Study (Sharon Project)

Deressa

Wondemagegnehu

Bogale

et al. 2020

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer

Cited by 60 publications

References 74 publications

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma

Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial

Short-Course 2-Dimensional Radiation Therapy in the Palliative Treatment of Esophageal Cancer in a Developing Country: A Phase II Study (Sharon Project)

Contact Info

Product

Resources

About